Study on the Comparative Efficacy and Safety of Intellan, Poly Herbal Product (Test Group) with Vinpocetine (Control Group) to Treat Dementia

Ghazal Fatima Naqvi, Safila Naveed, Aisha Sana, Asma Wazir, Sohail Hassan, Shereen, Tahreem Mujtaba, Nazia Tabassum, Qurat-Ul-Aen Ismail, Fatima Qamar

Abstract

This study aimed to compare the efficacy and safety of Polyherbal product Intellan with Vinpocetine in managing dementia and subject them to analysis by Mini metal state examination (MMSE) score, which is the most broadly perceived formal intellectual test. The MMSE was a 30-point test. This study was conducted at the Department of Medicine, Civil Hospital, Karachi, for six months. Patients were dispensed to get the test drug Intellan or controlled drug Vinpocetine. Keeping in consideration for 20% dropout in the test drug arm, with full appliance in the vinpocetine treatment arm, 150 subjects were in each arm. A total of 300 patients of both genders aged between 30 and 75 years who met the inclusion criteria participated in the study. The patients were evaluated prospectively for 24 weeks. The patients were advised follow-up visits weekly. Data were entered and analyzed using SPSS 12.0 (statistical software). The study groups were compared with the baseline characteristic, clinical presentation and history. Mean comparison was done by independent t-test and dependent t-test as appropriate, p≤0.05 was considered significant. No such study can be found that compare these drugs for treating dementia. In our study, mean MMSE before treatment, at 3 months and at 6 months was 8.91±4.12, 10.78±4.41, 13.54±4.54, respectively, while in group B, mean MMSE before treatment, at 3 months and at 6 months was 8.61±4.00, 10.74±4.18, 13.24±4.63, respectively. We found significant mean difference of MMSE before treatment with MMSE at 3 months, MMSE before treatment with MMSE at 6 months and MMSE at 3 months with MMSE at 6 months for both groups. An insignificant mean difference of MMSE at the 6th month s with study group (p=0.572) was found. Mean comparison was also done according to the study group s for stratified categories of gender, age, socio-economic status, education status, family history of dementia, living area, Alzheimer, epilepsy, diabetes mellitus, hypertension and body mass index.

 

Keywords: Intellan, Vinpocetine, mini-mental state examination, dementia, efficacy.

 

https://doi.org/10.55463/issn.1674-2974.49.9.26


Full Text:

PDF


References


COLLINS R, & MACMAHON S. Reliable assessment of the effects of treatment on mortality and major morbidity: clinical trials. Lancet, 2001, 357(9253): 373-383 https://doi.org/10.1016/S0140-6736(00)03651-5

STAESSEN JA, FAGARD R, & THIJS L. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet, 1997, 350(9080): 757-764 https://doi.org/10.1016/S0140-6736(97)05381-6

HEINRICH M, & Teoh H. Galanthamine from snowdrop – The development of a modern drug against Alzheimer’s disease from local Caucasian knowledge. Journal of Ethnopharmacology, 2004, 92: 147-162. https://doi.org/10.1016/j.jep.2004.02.012.

ZANGARA A. The psychopharmacology of huperzine A: An alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer’s disease. Pharmacology, Biochemistry, and Behavior, 2003, 75: 675-86. https://doi.org/10.1016/S0091-3057(03)00111-4.

WANG R, YAN H, & TANG, X-C. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine1. Acta Pharmacologica Sinica, 2006, 27: 1-26. https://doi.org/10.1111/j.1745-7254.2006.00255.x.

ADAMS L, GATCHEL J, & GENTRY C. Complementary and alternative medicine: Applications and implications for cognitive functioning in elderly populations. Alternative Therapies in Health and Medicine, 2001, 7: 52-61.

NAHIN R, FITZPATRICK A, WILLIAMSON J, BURKE G, et al. Use of Herbal Medicine and Other Dietary Supplements in Community-Dwelling Older People: Baseline Data from the Ginkgo Evaluation of Memory Study. Journal of the American Geriatrics Society, 2006, 54: 1725-1735. https://doi.org/10.1111/j.1532-5415.2006.00942.x.

PARK S-Y, & KIM D. Discovery of Natural Products from Curcuma longa that Protect Cells from Beta-Amyloid Insult: A Drug Discovery Effort against Alzheimer’s Disease. Journal of Natural Products, 2002, 65, 1227-1231. https://doi.org/10.1021/np010039x.

KIM D, KIM J-Y, & HAN Y. Alzheimer’s Disease Drug Discovery from Herbs: Neuroprotectivity from ??-Amyloid (1-42) Insult. Journal of Alternative and Complementary Medicine (New York, N.Y.), 2007, 13: 333-340. https://doi.org/10.1089/acm.2006.6107.

AMERY A, BIRKENHÄGER W, BULPITT CJ, et al. SYST-EUR: a multicenter trial on the treatment of isolated systolic hypertension in older adults: objectives, protocol, and organization. Aging Clinical and Experimental Research, 1991, 3: 287-302 https://doi.org/10.1007/BF03324024

FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 1975, 12(3), 189–198. https://doi.org/10.1016/0022-3956(75)90026-6

FORETTE FA, AMERY A, STAESSEN J, et al. Is prevention of vascular dementia possible? The Syst-Eur Vascular Dementia Project. Aging (Milan, Italy), 1991, 3(4): 373-382. https://doi.org/10.1007/BF03324039

GAGNON ML, LETENNEUR L, DARTIGUES JF et al. The validity of the Mini-Mental State Examination as a screening instrument for cognitive impairment and dementia in French older persons community residents. Neuroepidemiology, 1990, 9(3): 143-150, https://doi.org/10.1159/000110764

LAUNER LJ. Overview of incidence studies of dementia conducted in Europe. Neuroepidemiology, 1992, 11 (suppl 1) 2-13 https://doi.org/10.1159/000110954

LOEB C, & GANDOLFO C. Diagnostic evaluation of degenerative and vascular dementia. Stroke, 1983, 14(3): 399-401 https://doi.org/10.1161/01.str.14.3.399

HACHINSKI VC, ILIFF LD, ZILHKA E, et al. Cerebral blood flow in dementia. Archives of Neurology, 1975, 32(9): 632-637 https://doi.org/10.1001/archneur.1975.00490510088009

KNAPP M, & PRINCE M. Dementia UK: full report. London: Alzheimer’s Society; 2007. https://www.alzheimers.org.uk/about-us/policy-and-influencing/dementia-uk-report

KATZ S, FORD AB, MOSKOWITZ RW, et al. Studies of illness in the aged. Journal of the American Medical Association, 1963, 185: 914-919 https://doi.org/10.1001/jama.1963.03060120024016

BRETELER MMB. Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiology of Aging, 2000, 21(2): 153-160 https://doi.org/10.1016/S0197-4580(99)00110-4


Refbacks

  • There are currently no refbacks.